Document Type

Conference Proceeding - Restricted Access

Publication Date

3-8-2022

Publication Title

Journal of the American College of Cardiology

Abstract

Background: Amiodarone is a commonly used anti-arrhythmic drug in the elderly. The effect of amiodarone therapy in patients with pre-existing cardiac implantable electronic devices (CIEDs) undergoing transcatheter aortic valve replacement (TAVR) is not previously reported Methods: We retrospectively reviewed patients with pre-existing CIEDs undergoing TAVR at a large tertiary care hospital. Patients were grouped based on amiodarone exposure perioperatively (Am) vs no exposure (NoAm). Multivariate Cox-proportional Hazard ratio and Kaplan Meier curves were generated to evaluate mortality in these two groups Results: Of the 865 patients who underwent TAVR from 2012 to 2020, 113 patients (13.1%) had pre-existing CIEDs prior to TAVR. Am consisted of 15 (13.3%) patients (mean age 82.4 ± 10.5, 53.3% males) while NoAm included 98 (86.7%) patients (mean age 83.1 ± 9.4, 56% males). Atrial fibrillation was present in 86.7% of Am vs 65.3% of NoAm (P= 0.1751). Amiodarone use was associated with increased mortality after adjusting for baseline characteristics and presence of atrial fibrillation (HR 2.38, CI 1.19-4.75, P= 0.0138), with a median survival of 29 months in Am group versus 60 months in NoAm (P=0.005). Conclusion: Amiodarone use was independently associated with increased mortality in patients with CIEDs undergoing TAVR.

Volume

79

Issue

9 Suppl

First Page

208

Last Page

208

Download

Share

COinS